Alterome Therapeutics, Inc., a clinical stage biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the dosing of the first patient in AKTive-001, a Phase 1/1b trial of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain.
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced today that Goldman Sachs (NYSE:GS) recognized Eric Murphy, Ph.D., CEO and co-founder of Alterome, as one of the Most Exceptional Entrepreneurs of 2024 at its Builders and Innovators Summit in Healdsburg, California.
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers.
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.
Alterome Therapeutics, Inc., a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts.
$35 million extension round led by new investor Colt Ventures and co-led by existing investor OrbiMed with participation from all existing investors
Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing…